Neurocrine Biosciences (NBIX) is drawing attention after recent trading left the shares about 13% lower over the past 3 months and roughly 9% lower year to date, despite positive annual revenue and net income growth.

At a latest share price of $127.68, the stock’s short term share price momentum has been soft, yet the 1 year total shareholder return of 14.08% and 3 year total shareholder return of 31.56% indicate a stronger longer term picture.

If you are considering similar healthcare names with potential in next generation treatments, this could be a good moment to scan 36 healthcare AI stocks

So with shares weaker in recent months but longer term returns still positive, along with annual revenue and net income growth on the table, is Neurocrine Biosciences quietly undervalued here or is the market already pricing in its future growth?

Most Popular Narrative: 28.9% Undervalued

At $127.68, the most widely followed valuation narrative places Neurocrine Biosciences’ fair value at $179.59, suggesting a meaningful gap between price and modeled worth.

• A broad, late-stage and diversified CNS pipeline, including multiple Phase III programs targeting major depressive disorder and schizophrenia, leverages advances in precision medicine and increases visibility for future earnings, supporting potential future valuation multiple expansion.
• Ongoing internal innovation in biologics (such as bispecifics, ADCs, peptides), and a strong preclinical pipeline, allows Neurocrine to capitalize on industry advancements in drug modalities, expanding the addressable market and supporting long-term revenue growth.

Want to see what sits behind that fair value gap? The narrative leans heavily on compounded revenue gains, fatter margins, and a future earnings multiple that stands above the sector norm.

Result: Fair Value of $179.59 (UNDERVALUED)

However, this upbeat story can be knocked off course if pricing pressure on INGREZZA intensifies, or if Crenessity and the broader pipeline underdeliver versus expectations.

Another Angle On Valuation

That 28.9% gap to fair value hinges on future cash flows, but the current P/E of 26.8x tells a different story. It sits above the US Biotechs average of 16.7x, the peer average of 20.3x, and even the 23.2x fair ratio, which points to valuation risk if growth expectations cool.

This leads to a simple question for you: is the premium price reflecting genuine staying power, or is it stretching too far ahead of what the business delivers today?

Next Steps

After considering both the potential benefits and the valuation risks, it may be helpful to review the facts yourself and decide promptly where you stand. To understand what is driving the current optimism, take a closer look at the 4 key rewards

Looking for more investment ideas?

If you stop with just one stock, you could miss out on other opportunities that match your style, so put the Simply Wall St screener to work for you.

• Target companies that combine quality and attractive pricing by scanning 53 high quality undervalued stocks before the crowd pays attention.
• Prioritise resilience and steadier potential outcomes by reviewing 68 resilient stocks with low risk scores that may suit a more cautious approach.
• Spot potential future market favourites early by checking the screener containing 26 high quality undiscovered gems that many investors might not be watching yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.